文献速递心力衰竭与心肌病

无细胞疗法用于心力衰竭:人心血管祖细胞体外产生细胞外囊泡

Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors.
PubMed 文献 · Eur Heart J · 2018-01-01

该研究探讨了人诱导多能干细胞来源的心血管祖细胞(iPSC-Pg)和心肌细胞(iPSC-CM)分泌的细胞外囊泡(EV)对慢性心力衰竭的治疗作用及机制。在心肌梗死诱导的裸鼠模型中,iPSC-Pg来源的EV相比细胞注射能更显著改善心脏功能,减少左心室容积并提高射血分数,且EV富含与组织修复相关的miRNA。结论认为EV可能通过其特定miRNA特征发挥心脏保护作用,有望替代细胞移植。

要点

  • iPSC-Pg来源的EV在改善心功能方面优于细胞注射。
  • EV治疗显著降低左心室收缩末期容积(-11%, P<0.001)和舒张末期容积(-4%, P=0.002),提高LVEF(+14%, P<0.0001)。
  • EV富含与组织修复通路相关的保守miRNA,可能介导其心脏保护效应。

核心结论

  • iPSC-Pg分泌的EV对慢性心力衰竭有效,可能部分通过其特定miRNA特征及相关的不同心脏保护通路刺激发挥作用。

研究设计与样本

  • 研究从人iPSC-Pg和iPSC-CM分离EV,体外评估生物活性,并在199只裸鼠中诱导心肌梗死,3周后将LVEF≤45%的小鼠随机接受iPSC-CM(1.4×10^6, n=19)、iPSC-Pg(1.4×10^6, n=17)、iPSC-Pg来源的总EV(n=19)或PBS(对照, n=17)经超声引导下经皮注射至梗死周边心肌,7周后盲法评估心脏超声、组织学和基因表达。

主要发现

  • 体外实验中,EV被靶细胞内化,剂量依赖性地增加细胞存活、增殖和内皮细胞迁移,并刺激管腔形成。
  • 体内实验中,EV治疗相比基线显著改善心脏功能:左心室收缩末期容积降低11%(P<0.001),舒张末期容积降低4%(P=0.002),LVEF提高14%(P<0.0001)。
  • 基因表达谱显示EV治疗的心脏富集组织修复通路。

临床怎么用

  • EV可能作为细胞移植的替代品用于慢性心力衰竭治疗,因其具有处理和监管优势。

局限性

  • 研究仅在小鼠模型中进行,尚未在人体验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: We have shown that extracellular vesicles (EVs) secreted by embryonic stem cell-derived cardiovascular progenitor cells (Pg) recapitulate the therapeutic effects of their parent cells in a mouse model of chronic heart failure (CHF). Our objectives are to investigate whether EV released by more readily available cell sources are therapeutic, whether their effectiveness is influenced by the differentiation state of the secreting cell, and through which mechanisms they act. METHODS AND RESULTS: The total EV secreted by human induced pluripotent stem cell-derived cardiovascular progenitors (iPSC-Pg) and human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) were isolated by ultracentrifugation and characterized by Nanoparticle Tracking Analysis, western blot, and cryo-electron microscopy. In vitro bioactivity assays were used to evaluate their cellular effects. Cell and EV microRNA (miRNA) content were assessed by miRNA array. Myocardial infarction was induced in 199 nude mice. Three weeks later, mice with left ventricular ejection fraction (LVEF) ≤ 45% received transcutaneous echo-guided injections of iPSC-CM (1.4 × 106, n = 19), iPSC-Pg (1.4 × 106, n = 17), total EV secreted by 1.4 × 106 iPSC-Pg (n = 19), or phosphate-buffered saline (control, n = 17) into the peri-infarct myocardium. Seven weeks later, hearts were evaluated by echocardiography, histology, and gene expression profiling, blinded to treatment group. In vitro, EV were internalized by target cells, increased cell survival, cell proliferation, and endothelial cell migration in a dose-dependent manner and stimulated tube formation. Extracellular vesicles were rich in miRNAs and most of the 16 highly abundant, evolutionarily conserved miRNAs are associated with tissue-repair pathways. In vivo, EV outperformed cell injections, significantly improving cardiac function through decreased left ventricular volumes (left ventricular end systolic volume: -11%, P < 0.001; left ventricular end diastolic volume: -4%, P = 0.002), and increased LVEF (+14%, P < 0.0001) relative to baseline values. Gene profiling revealed that EV-treated hearts were enriched for tissue reparative pathways. CONCLUSION: Extracellular vesicles secreted by iPSC-Pg are effective in the treatment of CHF, possibly, in part, through their specific miRNA signature and the associated stimulation of distinct cardioprotective pathways. The processing and regulatory advantages of EV could make them effective substitutes for cell transplantation.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. El Harane N, Kervadec A, Bellamy V, et al. Acellular therapeutic approach for heart failure: in vitro production of extracellular vesicles from human cardiovascular progenitors. Eur Heart J. 2018. PMID: 29420830. doi:10.1093/eurheartj/ehy012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。